GlassScriptPhysician profile
James F Carsten
NPI 1194756023
$3,144.14
in general payments reported to CMS, 2019-2025
29 companies · $1,207 in 2025
The $1,207 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $757 · 2023: $101 · 2024: $1,079 · 2025: $1,207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,387.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,387.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,172.22 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $253.26 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $174.35 | 2022-2025 | Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $159.90 | 2022-2025 | |
| Lilly USA, LLC | $142.57 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $131.86 | 2022-2025 | Xifaxan, Trulance |
| Pfizer INC. | $102.44 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.97 | 2024-2025 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $85.86 | 2022 | |
| Boston Scientific Corporation | $73.21 | 2025 | Wavewriter Alpha Prime 16, General - Erectile Dysfunction |
| Takeda Pharmaceuticals U.S.A., INC. | $62.04 | 2022-2025 | Trintellix |
| Dexcom, INC. | $62.03 | 2022-2025 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $60.42 | 2025 | Auvelity |
| Astellas Pharma US INC | $57.26 | 2024-2025 | Veozah |
| Abbott Laboratories | $56.34 | 2022-2024 | Freestyle Libre 3 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $55.07 | 2024-2025 | Kyphon Express II Kyphopak Tray, Intellis Adaptivestim, Venaseal |
| Xeris Pharmaceuticals, INC. | $49.50 | 2024-2025 | Gvoke Hypopen |
| Exact Sciences Corporation | $48.67 | 2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $37.91 | 2022-2024 | Gardasil 9, Gardasil, Capvaxive |
| Sumitomo Pharma America, INC. | $37.26 | 2025 | Gemtesa |
| Dynavax Technologies Corporation | $37.25 | 2023-2024 | Heplisav-B |
| Inspire Medical Systems, INC. | $33.65 | 2025 | Inspire |
| Shield Therapeutics INC | $32.00 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $30.90 | 2024 | Voquezna |
| Amarin Pharma, INC. | $23.00 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $21.00 | 2022 | |
| Daiichi Sankyo INC. | $20.39 | 2024 | Injectafer |
| E.R. Squibb & Sons, L.L.C. | $17.02 | 2025 | Eliquis |
| Amgen INC. | $12.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Carsten listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.